Target Points in Trastuzumab Resistance

International Journal of Breast Cancer - Tập 2012 - Trang 1-9 - 2012
Sahar Shojaei1, Mossa Gardaneh1, A Rahimi Shamabadi1
1National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Boulevard, Tehran-Karaj HWY, Km 15, Tehran 1497716316, Iran

Tóm tắt

Epidermal growth factor (EGF) family of receptors is involved in cell growth and differentiation. The human EGF2 (HER2) lacks natural ligands, and correlation between HER2 levels and carcinogenesis makes the receptor an ideal candidate for targeted therapy in breast cancer. Trastuzumab is a humanized antibody applied against HER2-positive breast tumors in clinic. Metastatic tumors respond well to trastuzumab therapy for the first year, but development of antibody resistance helps the tumors to regrow allowing the disease to progress. Trastuzumab resistance is shaped via a range of intracellular signaling pathways that are interconnected and share in key effector molecules. Identification of a common node central to these resistance pathways could provide an ultimate solution for trastuzumab resistance in breast and other cancers.

Từ khóa


Tài liệu tham khảo

10.3322/CA.2007.0010

10.1007/978-3-540-28266-2_38

2001, Annals of Oncology, 12, S3

10.1158/1078-0432.CCR-06-2405

10.1634/theoncologist.8-4-307

1998, Journal of Clinical Oncology, 16, 2659, 10.1200/JCO.1998.16.8.2659

10.120/JCO.2002.09.094

10.1056/NEJM199405053301802

1998, Journal of the National Cancer Institute, 90, 1346, 10.1093/jnci/90.18.1346

1987, Science, 235, 177, 10.1126/science.3798106

1989, Science, 244, 707, 10.1126/science.2470152

1993, Journal of the National Cancer Institute, 85, 1230, 10.1093/jnci/85.15.1230

2004, Breast Disease, 20, 25, 10.3233/BD-2004-20104

10.1007/s10549-004-7260-y

1998, Oncology, 55, 33, 10.1159/000011832

10.1056/NEJM200103153441101

10.1016/j.stem.2007.08.014

10.1038/onc.2008.207

10.1046/j.1365-2184.36.s.1.6.x

10.1074/jbc.M205692200

10.1074/jbc.M410491200

2004, Journal of the National Cancer Institute, 96, 926, 10.1093/jnci/djh166

10.1073/pnas.89.10.4285

10.1056/NEJM200103153441101

10.1158/0008-5472.CAN-10-1872

10.1016/j.canlet.2005.01.041

10.1158/0008-5472.CAN-03-3900

10.1158/1078-0432.CCR-04-0225

10.1200/JCO.20.3.719

10.1200/JCO.2007.11.6699

2001, Cancer Research, 61, 4744

10.1093/annonc/mdi059

2001, Cancer Research, 61, 4892

10.1073/pnas.0812059106

10.1038/sj.bjc.6602930

10.1016/j.ccr.2004.06.022

10.1016/j.ccr.2007.08.030

10.1093/jnci/djk134

2002, Cancer Research, 62, 4132

10.1158/0008-5472-CAN-04-3913

2000, Oncogene, 19, 1647, 10.1038/sj.onc.1203470

10.1158/0008-5472.CAN-08-2089

10.1002/ijc.10410

2003, Journal of Immunology, 171, 5124, 10.4049/jimmunol.171.10.5124

10.1093/emboj/16.7.1647

10.1016/j.yexcr.2004.12.008

2002, Cancer Research, 62, 3151

10.1200/JCO.2008.21.4437

10.1200/JCO.2006.07.0649

10.1242/jcs.00786

10.1002/iub.303

10.1007/s10555-007-9107-6

10.1158/0008-5472.CAN-07-2343

10.1210/me.2007-0449

10.1038/onc.2010.209

2002, Clinical Cancer Research, 8, 347

10.1016/S1521-690X(03)00045-9

2001, Journal of the National Cancer Institute, 93, 1852, 10.1093/jnci/93.24.1852

10.1038/sj.onc.1204091

10.1038/ncponc0509

10.1158/0008-5472.CAN-04-3841

10.1056/NEJMcibr043143

10.1200/JCO.2009.27.7814

2005, Cell Cycle, 4, 87, 10.4161/cc.4.1.1360

2001, Annals of Oncology, 12, S21

10.1073/pnas.1014835108

10.1093/annonc/mdp304

10.1056/NEJMoa021153

10.1038/onc.2010.151

10.1016/S0301-472X(99)00089-2

10.1038/74704

2004, Nature Reviews Cancer, 4, 470, 10.1038/nrc1366

2000, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9

10.1016/S0955-0674(97)80062-2

10.1007/s10549-009-0546-3

1993, Blood, 82, 2296, 10.1182/blood.V82.8.2296.2296

10.1016/j.ccr.2010.10.025

10.1038/nm.2309

10.1200/JCO.2009.27.8549

10.1073/pnas.96.4.1415

Thông tin
Thông tin xuất bản

International Journal of Breast Cancer

Tập 2012

1-9

Thông tin tác giả